Efficacy and safety of UI05MSP015CT in functional dyspepsia: A randomized, controlled trial

Hyuk Yoon, Dong Ho Lee, Yong Hyun Lee, Ju Cheol Jeong, Soo Teik Lee, Myung Gyu Choi, Seong Woo Jeon, Ki Nam Shim, Gwang Ho Baik, Jae Gyu Kim, Jeong Seop Moon, In Kyung Sung, Sang Kil Lee, Poong Lyul Rhee, Hwoon Yong Jung, Bong Eun Lee, Hyun Soo Kim, Sang Gyun Kim, Kee Myung Lee, Jae Kyu SeongJin Seok Jang, Jong Jae Park

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)


    Background/Aims: To evaluate the efficacy and safety of a controlled release, once-daily formulation of mosapride (UI05MSP015CT) in patients with functional dyspepsia (FD). Methods: Patients with FD were randomly assigned (1:1) to receive either UI05MSP015CT (15 mg once a day, study group) or mosapride (5 mg three times a day, control group) and corresponding placebo for 4 weeks. The primary endpoint was a change in the gastrointestinal symptom score (GIS) evaluated at enrollment and after 4 weeks. Secondary endpoints were changes in the Nepean Dyspepsia Index-Korean version (NDI-K), rate of satisfactory symptom relief, and rate of adverse events. Results: A total of 138 patients were enrolled (female, 73.9%; mean age, 44.0±15.4 years). After excluding patients who violated the study protocol, 59 and 58 patients from the study and control groups, respectively, were included in the per-protocol analysis. No difference was observed in drug compliance between the control and study groups (97.07%±4.52% vs 96.85%±6.05%, p=0.870). Changes in GIS scores were –9.69±6.44 and –10.01±5.92 in the study and control groups. The mean difference in GIS change between groups was 0.33 (95% confidence interval, –1.75 to 2.41), demonstrating non-inferiority of UI-05MSP015CT (p=0.755). The rate of satisfactory symptom relief was not different between the study and control groups (39.0% vs 56.9%, p=0.053). No differences in change in NDI-K score (14.3 vs 16.9, p=0.263) or rates of adverse events (12.9% vs. 4.4%, p=0.062) were observed between the study and control groups. Conclusions: Once-daily mosapride is not inferior to conventional mosapride in efficacy and is safe in patients with FD.

    Original languageEnglish
    Pages (from-to)516-522
    Number of pages7
    JournalGut and liver
    Issue number5
    Publication statusPublished - 2018 Sep


    • Compliance
    • Efficacy
    • Functional dyspepsia
    • Mosapride
    • Randomized clinical trial

    ASJC Scopus subject areas

    • Hepatology
    • Gastroenterology


    Dive into the research topics of 'Efficacy and safety of UI05MSP015CT in functional dyspepsia: A randomized, controlled trial'. Together they form a unique fingerprint.

    Cite this